Latest & greatest articles for liraglutide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on liraglutide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on liraglutide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for liraglutide

21. [Assessment of the LEADER study on liraglutide - rapid report]

[Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09 [Assessment of the LEADER study on liraglutide - rapid report] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Bewertung der studie LEADER zu liraglutid: rapid report; auftrag A17-09. [Assessment of the LEADER study on liraglutide - rapid report] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 530. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH

2018 Health Technology Assessment (HTA) Database.

22. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. (PubMed)

Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. 30508430 2018 12 03 1539-3704 2018 Dec 04 Annals of internal medicine Ann. Intern. Med. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. 10.7326/M18-1569 Gilbert Matthew P MP Larner College of Medicine at The University of Vermont, South Burlington, Vermont (M.P.G.). Bain Stephen C SC Institute

2018 Annals of Internal Medicine

23. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials

Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials The cardiovascular safety of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management at a dose of 3.0 mg, was evaluated post hoc using data from 5908 participants in 5 randomized, double-blind, placebo-controlled clinical trials. Participants were randomized to liraglutide or a comparator group (placebo or orlistat (...) ). The objective was to evaluate whether cardiovascular risk was increased with liraglutide treatment. The primary composite outcome of this time-to-event analysis was the first occurrence of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. These cardiovascular events were adjudicated prospectively for three of the trials and retrospectively for two trials by an event adjudication committee. The primary outcome was analyzed using a Cox proportional hazards model, stratified by trial

Full Text available with Trip Pro

2017 EvidenceUpdates

24. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial Women with polycystic ovary syndrome (PCOS) were treated with the GLP-1 receptor agonist liraglutide to investigate the effect on liver fat content, visceral adipose tissue (VAT) and the prevalence of nonalcoholic fatty liver disease (NAFLD). In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m2 and/or insulin resistance, were treated (...) with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks. Liver fat content was assessed by 1 HMR spectroscopy, VAT by MRI, body composition by DXA, and glucose metabolism by oral glucose tolerance test. Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P < .01). Sex-hormone-binding-globulin (SHBG) levels increased by 19% (P = .03), and free testosterone decreased by 19% (P = .054

Full Text available with Trip Pro

2017 EvidenceUpdates

25. Saxenda (liraglutide) - for treatment of overweight

Saxenda (liraglutide) - for treatment of overweight Saxenda® (liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Saxenda® (liraglutide) Conclusion Saxenda is indicated for treatment of overweight in people with a BMI >30 or a BMI between 27 and 30 with at least one weight-related complication as an adjunct to a reduced-calorie diet and physical activity. Saxenda contains liraglutide, a long-acting glucagon-like peptide-1 (GLP-1 analogue (...) ) and is administered subcutaneously once daily. The dose is escalated over a period of four weeks to the daily maintenance dose of 3 mg liraglutide. Saxenda's exact mechanism of action in weight loss is not entirely clear. Overall, treatment with Saxenda produces a placebo-adjusted weight loss of 5.2%. The weight loss achieved was statistically significantly greater in women compared to men. Saxenda treatment gave a continuous decrease in weight during the first 40 weeks of treatment, after which the weight loss

2017 Danish Pharmacotherapy Reviews

26. Liraglutide and Renal Outcomes in Type 2 Diabetes. (PubMed)

Liraglutide and Renal Outcomes in Type 2 Diabetes. In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes (...) in patients with type 2 diabetes are unknown.We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease. The risk of renal outcomes was determined with the use of time-to-event analyses with an intention-to-treat approach

Full Text available with Trip Pro

2017 NEJM

27. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.To determine the effects (...) of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders.This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through

Full Text available with Trip Pro

2017 EvidenceUpdates

28. Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used

Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition used To re-analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V, in which the once-daily, fixed ratio combination of insulin degludec/liraglutide (IDegLira) was compared with basal insulin therapy.Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic (...) hypoglycaemia definitions, rates were consistently lower with IDegLira vs insulin degludec (IDeg) and IGlar U100. Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time. The definitions of confirmed and ADA-documented symptomatic hypoglycaemia did not have a significant effect on the treatment difference between IDegLira and IDeg, liraglutide

Full Text available with Trip Pro

2017 EvidenceUpdates

29. Obese, overweight with risk factors: liraglutide (Saxenda)

Obese, overweight with risk factors: liraglutide (Saxenda) Obese, o Obese, ov verweight with risk factors: lir erweight with risk factors: liraglutide aglutide (Sax (Saxenda) enda) Evidence summary Published: 27 June 2017 nice.org.uk/guidance/es14 pathways K Ke ey points y points The content of this evidence summary was up-to-date in June 2017. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Regulatory (...) status: Regulatory status: New medicine. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Liraglutide (Saxenda) received a European marketing authorisation in March 2015 and was launched in the UK in January 2017. It is licensed as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial BMI of: 30 kg/m² or more (obese), or from 27 kg/m² to less than 30 kg/m² (overweight) in the presence of at least one weight

2017 National Institute for Health and Clinical Excellence - Advice

30. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program

Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program To describe amylase/lipase activity levels and events of acute pancreatitis (AP) in the SCALE (Satiety and Clinical Adiposity-Liraglutide Evidence in individuals with and without diabetes) weight-management trials.Secondary analyses were performed on pooled data (...) from four trials (N = 5,358 with BMI ≥30, or 27 to <30 kg/m2 with ≥1 comorbidity). Of these, 1,723 had normoglycemia, 2,789 had prediabetes, and 846 had type 2 diabetes. Participants were randomized to liraglutide 3.0 mg (n = 3,302), liraglutide 1.8 mg (n = 211, only type 2 diabetes), or placebo (n = 1,845). Relationships between baseline characteristics and amylase/lipase activity at baseline and during treatment were investigated.Over 56 weeks, liraglutide 3.0 mg versus placebo was associated

Full Text available with Trip Pro

2017 EvidenceUpdates

31. Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures (PubMed)

Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures 28827991 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Anticonvulsant effect of liraglutide, GLP-1 agonist by averting a change in GABA and brain glutathione level on picrotoxin-induced seizures. 752-754 10.17179/excli2017-283 Gupta Gaurav G School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. School of Medicine and Public

Full Text available with Trip Pro

2017 EXCLI journal

32. Recent update on biological activities and pharmacological actions of liraglutide (PubMed)

Recent update on biological activities and pharmacological actions of liraglutide 28827989 2018 11 13 1611-2156 16 2017 EXCLI journal EXCLI J Recent update on biological activities and pharmacological actions of liraglutide. 742-747 10.17179/excli2017-323 Tiwari Juhi J School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. Gupta Gaurav G School of Pharmacy, Jaipur National University, Jagatpura 302017, Jaipur, India. School of Medicine and Public Health, University

Full Text available with Trip Pro

2017 EXCLI journal

33. Diabetes: avoid insulin degludec in combination with liraglutide

Diabetes: avoid insulin degludec in combination with liraglutide Prescrire IN ENGLISH - Spotlight ''Diabetes: avoid insulin degludec in combination with liraglutide'', 1 May 2017 {1} {1} {1} | | > > > Diabetes: avoid insulin degludec in combination with liraglutide Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Diabetes: avoid insulin degludec (...) in combination with liraglutide In patients with type 2 diabetes, the combination of insulin degludec and liraglutide in an injection pen has more disadvantages than advantages. In patients with type 2 diabetes, when metformin does not provide satisfactory glycaemic control, there is no evidence that the combination of liraglutide with an insulin is of any benefit in preventing clinical complications of diabetes. A fixed-dose combination in an injection pen of insulin degludec, a long-acting insulin

2017 Prescrire

34. GLP-1 Agonists (liraglutide)

GLP-1 Agonists (liraglutide) MED CHECK - TIP December 2016 / Vol.2 No.6 · Page 27 -The Informed Prescriber C N o 6 M ED HECK Volume 2 December 2 0 1 6 Nivolumab (brand name: Opdivo) Editorial: Don’t be misled by new “mab” drugs New Products New anticancer drug Nivolumab (brand name: Opdivo) GLP-1 Agonists (liraglutide etc.) CONTENTS (December 2016, Vol. 2, No. 6) 28 29 35 Benefit and harm on survival offset each other: strict restriction on use is needed GLP-1 Agonists (liraglutide) No evidence (...) amounted to over 100 billion yen [4]. However, just like other hypoglycemic agents, they were approved as “new products” only for their lowering effect on glycohemoglobin (HbA1c), a surrogate endpoint. Later on, because of the reasons described in the column (P,38)of this GLP-1 Agonists (liraglutide etc.) No evidence of improving prognosis in patients with diabetes Not recommended Note 1: Non-inferiority and superiority trials Superiority trial: a trial to show the superiority of an intervention

2017 Med Check - The Informed Prescriber

35. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. (PubMed)

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 (...) diabetes.In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-calorie diet and increased physical activity. Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post

Full Text available with Trip Pro

2017 Lancet

36. Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes

Randomised controlled trial: Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Liraglutide, a GLP-1 receptor agonist, prevents cardiovascular outcomes in patients with type 2 diabetes Article Text Therapeutics/Prevention Randomised

2017 Evidence-Based Medicine (Requires free registration)

37. Assessment of the LEADER study on liraglutide - rapid report

Assessment of the LEADER study on liraglutide - rapid report 1 Translation of the executive summary of the rapid report Bewertung der Studie LEADER zu Liraglutid (Version 1.0; Status: 23 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive Summary IQWiG Reports – Commission No. A17-09 Assessment of the LEADER study on liraglutide 1 Executive (...) summary of rapid report A17-09 Version 1.0 Assessment of the LEADER study on liraglutide 23 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Assessment of the LEADER study on liraglutide Commissioning agency: Federal Joint Committee Commission awarded on: 8 March 2017 Internal Commission No.: A17-09 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

38. Xultophy (insulin degludec and liraglutide) - type 2 diabetes

Xultophy (insulin degludec and liraglutide) - type 2 diabetes Xultophy® (insulin degludec and liraglutide) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Xultophy® (insulin degludec and liraglutide) Conclusion Xultophy® (insulin degludec and liraglutide) is a combination product for treatment of type 2 diabetes administered by one daily injection consisting of insulin degludec and the GLP-1 receptor agonist (GLP1-RA) liraglutide. The dose (...) is administered by a pre-filled injection pen with a fixed-ratio combination of insulin degludec and liraglutide, which offers a less flexible dose adjustment. The maximum daily dose is 50 dose steps corresponding to 50 units insulin degludec/1.8 mg liraglutide. In clinical studies, Xultophy has been demonstrated to reduce HbA1c more than both insulin degludec, liraglutide and insulin glargin in combination with existing treatment with different oral antidiabetics. Compared to the above-mentioned insulins

2017 Danish Pharmacotherapy Reviews

39. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial (PubMed)

Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8 mg/d versus continued sitagliptin.A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes (...) who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100 mg/d) and metformin (≥1500 mg daily) for ≥90 days were randomized to either switch to liraglutide (n = 203) or continue sitagliptin (n = 204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54

Full Text available with Trip Pro

2016 EvidenceUpdates

40. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (PubMed)

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial To investigate effects of dipeptidyl peptidase-4 inhibitor (DPP-4I) sitagliptin or glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide treatment on renal hemodynamics, tubular functions, and markers of renal damage in overweight patients with type 2 diabetes without chronic kidney disease (CKD (...) ).In this 12-week, randomized, double-blind trial, 55 insulin-naïve patients with type 2 diabetes (mean ± SEM: age 63 ± 7 years, BMI 31.8 ± 4.1 kg/m2, glomerular filtration rate [GFR] 83 ± 16 mL/min/1.73 m2; median [interquartile range]: albumin-to-creatinine ratio (ACR) 1.09 mg/mmol [0.47-3.31]) received sitagliptin (100 mg/day), liraglutide (1.8 mg/day), or matching placebos. GFR (primary end point) and effective renal plasma flow (ERPF) were determined by inulin and para-aminohippuric acid clearance

Full Text available with Trip Pro

2016 EvidenceUpdates